23:38 , Nov 22, 2016 |  BC Week In Review  |  Clinical News

ABTL0812: Ph II started

Ability began an open-label, Spanish and French Phase II trial to evaluate 1,500-3,900 mg oral ABTL0812 as first-line therapy in combination with paclitaxel and carboplatin in 80 patients with advanced or recurrent endometrial cancer or...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Ability Pharmaceuticals, SciClone deal

Ability granted SciClone exclusive rights to develop and commercialize ABTL0812 in Taiwan, Vietnam and China, including Hong Kong and Macau. Ability will receive up to $20 million, which includes an undisclosed upfront payment and milestones....
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

ABTL0812: Phase Ib data

An open-label, dose-escalation, Spanish Phase I/Ib trial in 29 patients with advanced solid tumors showed that once-daily oral ABTL0812 for 28-day cycles was well tolerated with no dose-limiting toxicities (DLTs) reported. The MTD was not...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

AB Therapeutics preclinical data

In mouse models of NSCLC, ABTL0812 and ABTL1014 each reduced tumor growth by 70% vs. both placebo and Taxotere docetaxel. The company plans to start Phase I testing with 1 of the undisclosed small molecules...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Clinical News

AB Therapeutics preclinical data

In mouse models of NSCLC, ABTL0812 and ABTL1014 each reduced tumor growth by 70% vs. both placebo and Taxotere docetaxel. The company plans to start Phase I testing with 1 of the undisclosed small molecules...